DOCSLIB.ORG

Natalizumab for Multiple Sclerosis: a Case in Point for the Impact of Translational Neuroimmunology

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Natalizumab for Multiple Sclerosis: a Case in Point for the Impact of Translational Neuroimmunology Natalizumab for Multiple Sclerosis: A Case in Point for the Impact of Translational Neuroimmunology This information is current as Afsaneh Shirani and Olaf Stüve of September 26, 2021. J Immunol 2017; 198:1381-1386; ; doi: 10.4049/jimmunol.1601358 http://www.jimmunol.org/content/198/4/1381 Downloaded from References This article cites 58 articles, 6 of which you can access for free at: http://www.jimmunol.org/content/198/4/1381.full#ref-list-1 Why The JI? Submit online. http://www.jimmunol.org/ • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average by guest on September 26, 2021 Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2017 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Th eJournal of Translating Immunology Immunology Natalizumab for Multiple Sclerosis: A Case in Point for the Impact of Translational Neuroimmunology Afsaneh Shirani and Olaf Stuve€ Advances in translational neuroimmunology over the last flammation (4). Therefore, inhibition of leukocyte trafficking two decades have revolutionized the treatment of relaps- across the inflamed blood–brain barrier should provide an ef- ing forms of multiple sclerosis. A pathological hallmark fective anti-inflammatory therapy for MS (5). Natalizumab is a of multiple sclerosis is the presence of leukocytes in the a mAb that blocks the 4-integrin–mediated leukocyte– areas of disease activity in the CNS. Natalizumab inhibits endothelial interaction, resulting in inhibition of trafficking the trafficking of lymphocytes from the blood into the of lymphocytes from the blood into the CNS (6). Natalizu- brain and spinal cord by blocking the adhesion molecule mab was approved by the U.S. Food and Drug Administra- a tion (FDA) for the treatment of RRMS only 12 y after the Downloaded from 4-integrin. Representing the enormous success of a molecular targeted approach, natalizumab was the first discovery of its target molecule in 1992 and 7 y after the mAb approved for the treatment of relapsing–remitting beginning of its first clinical trial, a time line that is rather fast multiple sclerosis. However, only a few months after for development of new drugs (7). This was based on con- vincing clinical and radiological benefits in phase III trials (6). its approval, natalizumab was withdrawn from the mar- However, a few months after its FDA approval, natalizumab ket because of an unanticipated life threatening adverse was taken off the market because of a life-threatening com- http://www.jimmunol.org/ effect: progressive multifocal leukoencephalopathy. plication: progressive multifocal leukoencephalopathy (PML). Natalizumab was later reintroduced with required ad- Natalizumab was later reinstated with required adherence to a herence to a strict monitoring program. In this article, strict monitoring program. we review the bench-to-bedside journey of natalizumab, Although the bench-to-bedside journey of natalizumab along with the lessons learned from postmarketing stud- highlights the value of a molecular targeted approach in de- ies. The Journal of Immunology, 2017, 198: 1381– veloping new therapeutics for MS, natalizumab-associated 1386. PML emphasizes the importance of continued long-term post- marketing safety surveillance, sometimes warranting a bedside- by guest on September 26, 2021 he last two decades have witnessed a revolution in the to-bench switch. In this article, we review the translational treatment landscape for relapsing forms of multiple journey of natalizumab along with the lessons learned from T sclerosis (MS), with the introduction of mAb-based postmarketing studies. therapies and novel oral agents. This has been possible through Mechanism of action translational neuroimmunology approaches in MS research and Leukocyte trafficking across the blood–brain barrier involves the advent of modern tools in neuroimmunology, neurobiology, overlapping sequential steps, including tethering and rolling, and neuroimaging (1). The discovery and bench-to-bedside chemoattraction, cell adhesion, and proteolytic degradation of journey of natalizumab, as the first therapeutic mAb approved biological membranes (5). Rolling on endothelial cell walls for the treatment of relapsing forms of MS, is a case in point. allows leukocytes to identify the proper array of chemoattractants MS is a chronic inflammatory, autoimmune, demyelinating, and integrin ligands (5). Natalizumab (Tysabri; Biogen Idec, and neurodegenerative disease of the white and gray matter Cambridge, MA) is a humanized rIgG4 mAb that blocks ∼ a within the CNS. Affecting 2.5 million individuals world- the 4-integrin–mediated leukocyte–endothelial interaction, wide, MS is the most common cause of neurologic disability resulting in inhibition of trafficking of lymphocytes from the in young adults (2). Approximately 85% of patients pre- blood into the CNS (6). Natalizumab binds to a4-integrin sent with relapsing–remitting MS (RRMS) at diagnosis, which on lymphocytes, as well as on myeloid cells, thereby inhibiting is characterized by alternating episodes of neurologic disability their migration into the CNS tissue (8). (relapses) followed by complete or partial recovery from symp- The discovery of the target molecule for natalizumab dates toms (3). A major pathologic hallmark of MS is chronic in- back to 1992 (9); however, the interaction between endothelium Department of Neurology and Neurotherapeutics, University of Texas Southwestern Abbreviations used in this article: AFFIRM, Natalizumab Safety and Efficacy in Relapsing- Medical Center, Dallas, TX 75390; and Neurology Section, VA North Texas Health Remitting Multiple Sclerosis; EAE, experimental autoimmune encephalomyelitis; EDSS, Care System, Medical Service, Dallas VA Medical Center, Dallas, TX 75216 expanded disability status scale; FDA, U.S. Food and Drug Administration; GA, glatiramer acetate; IRIS, immune reconstitution inflammatory syndrome; JCV, John Cunningham ORCID: 0000-0002-8866-6426 (A.S.). virus; MRI, magnetic resonance imaging; MS, multiple sclerosis; PML, progressive multi- Received for publication August 5, 2016. Accepted for publication December 6, 2016. focal leukoencephalopathy; RRMS, relapsing–remitting MS; SENTINEL, Safety and Ef- ficacy of Natalizumab in Combination with IFN-b1a in Patients with Relapsing-Remitting Address correspondence and reprint requests to Dr. Olaf Stuve,€ Neurology Section, VA Multiple Sclerosis; VLA-4, very late activating Ag 4. North Texas Health Care System, Medical Service, 4500 South Lancaster Road, Dallas, TX 75216. E-mail address: [email protected] Copyright Ó 2017 by The American Association of Immunologists, Inc. 0022-1767/17/$30.00 www.jimmunol.org/cgi/doi/10.4049/jimmunol.1601358 1382 TRANSLATING IMMUNOLOGY: NATALIZUMAB IN MULTIPLE SCLEROSIS and lymphocytes has been intriguing scientists since the two doses of monthly natalizumab (3 and 6 mg/kg) versus mid-1960s, when it was first demonstrated in rats that lymphocytes placebo for 6 mo, followed by a 6-mo observation in patients enter lymph nodes through specialized postcapillary blood vessels with relapsing MS, showed that both of the tested doses called high endothelial venules (10). Several studies focused on resulted in fewer inflammatory brain lesions and fewer re- mapping of molecules involved in the process of lymphocyte lapses over a 6-mo period (20). Later, a phase II randomized migration highlighted the role of integrins and selectins, partic- double-blind placebo-controlled trial, Glatiramer Acetate and ularly the cellular adhesion molecules, including ICAM and Natalizumab Combination Evaluation, compared the safety VCAM (11–13). The integrin very late activating Ag 4 (VLA-4; and tolerability of combination therapy with natalizumab plus a 4b1-integrin) was identified as a receptor for VCAM-1, and the glatiramer acetate (GA) versus GA only (21). Both groups had VCAM-1/VLA-4 ligand–receptor pair was suggested to play a a similar incidence of infection and infusion reactions, and major role in the recruitment of mononuclear leukocytes to no hypersensitivity reactions were reported. Therefore, it was inflammatory sites in vivo (14). In the early 1990s, scientists concluded that the combination of natalizumab and GA at Stanford University and Athena Neurosciences collaborated seemed safe and well tolerated during a 6-mo treatment in an attempt to further identify the adhesion receptors in- period (21). volved in lymphocyte homing to inflamed brain endothelium, using the animal model of MS, experimental autoimmune Pivotal phase III trials encephalomyelitis (EAE) (9). Using an in vitro adhesion assay The FDA approval of natalizumab was based on two pivotal phase on frozen sections of EAE CNS tissue, they showed that III trials in patients with relapsing forms of MS: the Natalizumab Downloaded from leukocytes selectively bind to the lumen of the vessels, a Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis
Load more

Recommended publications
  • Exploring the Association Between Monoclonal Antibodies and Depression and Suicidal Ideation and Behavior: a Vigibase Study
    Drug Safety https://doi.org/10.1007/s40264-018-00789-9 ORIGINAL RESEARCH ARTICLE Exploring the Association between Monoclonal Antibodies and Depression and Suicidal Ideation and Behavior: A VigiBase Study Lotte A. Minnema1,2 · Thijs J. Giezen2,3 · Patrick C. Souverein1 · Toine C. G. Egberts1,4 · Hubert G. M. Leufkens1 · Helga Gardarsdottir1,4,5 © The Author(s) 2019 Abstract Introduction Several monoclonal antibodies (mAbs) have been linked to neuropsychiatric adverse efects in patients, includ- ing depression and suicidal ideation and behavior. Objective The aim of this study was to quantify and characterize spontaneously reported adverse drug reactions (ADRs) of depression and suicidal ideation and behavior related to mAb users, and to explore a possible association with their mecha- nism of action. Methods We included mAb ADRs that were reported in VigiBase, and identifed those related to depression and suicidal ideation and behavior. Reporting odds ratios (RORs) were estimated for each mAb (bevacizumab as the reference) and according to their infuence on the immune system (not directly targeting [reference], stimulating, or suppressing). Those suppressing the immune system were further divided into their intended indication (auto-immune diseases, cancer). Results Overall, 2,924,319 ADRs for 44 mAbs were included; 9455 ADRs were related to depression and 1770 were related to suicidal ideation and behavior. The association was strongest for natalizumab and belimumab, both for depression (ROR 5.7, 95% confdence interval [CI] 5.0–6.4; and ROR 5.1, 95% CI 4.2–6.2) and suicidal ideation and behavior (ROR 12.0, 95% CI 7.9–18.3; and ROR 20.2, 95% CI 12.4–33.0).
    [Show full text]
  • Neuromyelitis Optica Spectrum Disorder
    © Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 | Fax 503-947-2596 Drug Class Review with New Drug Evaluation: Biologics for Autoimmune Disorders-Neuromyelitis Optica Spectrum Disorder Date of Review: April 2021 Date of Last Review: n/a Dates of Literature Search: 1/1/1996 – 1/20/2021 Generic Name: Brand Name (Manufacturer): Eculizumab Soliris® (Alexion Pharmaceuticals) Inebilizumab-cdon Uplizna™ (Viela Bio) Satralizumab-mwge Enspryng™ (Genentech/Roche) Dossiers Received: Yes Current Status of PDL Class: See Appendix 1. Purpose for Class Update: To define place in therapy for 3 immunosuppressive agents, eculizumab, inebilizumab-cdon, and satralizumab-mwge, recently approved by the Food and Drug Administration (FDA) for the treatment adults with neuromyelitis optica spectrum disorder (NMOSD). Research Questions: 1. What is the effectiveness of eculizumab, inebilizumab, and satralizumab in reducing time to relapse in adult patients with NMOSD who are anti-aquaporin-4 (AQP4) antibody positive? 2. What are the harms of eculizumab, inebilizumab-cdon and satralizumab in adults with NMOSD? 3. Is there comparative evidence that eculizumab, inebilizumab, and satralizumab differ in efficacy or harms for management of NMOSD? 4. Are there certain sub-populations (based on age, gender, ethnicity, comorbidities, disease duration or severity) in which eculizumab, inebilizumab, or satralizumab may be beneficial
    [Show full text]
  • Middle Level IM-MS and CIU Experiments for Improved Therapeutic Immunoglobulin Subclass Fingerprinting ACS Paragon Plus Environment Analytical Chemistry T
    Middle level IM-MS and CIU experiments for improved therapeutic immunoglobulin subclass fingerprinting ACS Paragon Plus Environment Analytical Chemistry T. Botzanowski, O. Hernandez-Alba, M. Malissard, E. Wagner-Rousset, E. Desligniere, O. Colas, F. Haeuw J., A. Beck, S. Cianferani To cite this version: T. Botzanowski, O. Hernandez-Alba, M. Malissard, E. Wagner-Rousset, E. Desligniere, et al.. Middle level IM-MS and CIU experiments for improved therapeutic immunoglobulin subclass fingerprinting ACS Paragon Plus Environment Analytical Chemistry. Analytical Chemistry, American Chemical Society, 2020, 92 (13), pp.8827-8835. 10.1021/acs.analchem.0c00293. hal-02960844 HAL Id: hal-02960844 https://hal.archives-ouvertes.fr/hal-02960844 Submitted on 8 Oct 2020 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Analytical Chemistry This document is confidential and is proprietary to the American Chemical Society and its authors. Do not copy or disclose without written permission. If you have received this item in error, notify the sender and delete all copies.
    [Show full text]
  • Submission of Eculizumab for NMOSD to PBAC Meeting November 2020
    PBAC Secretariat MDP 952 Department of Health and Ageing GPO Box 9848 Canberra ACT 2601 7 October 2020 Re: Submission of eculizumab for NMOSD to PBAC meeting November 2020 This is a joint submission to the Pharmaceutical Benefits Advisory Committee (PBAC) in relation to eculizumab (Soliris) for neuromyelitis optica spectrum disorder (NMOSD) from MS Research Australia, the Centre for Community-Driven Research and MS Australia. • MS Research Australia is the largest national not-for-profit organisation dedicated to funding MS discoveries and coordinating MS research in Australia. • The Centre for Community-Driven Research is a non-profit organisation with expertise in gathering patient experience and expectations data. • MS Australia is the national voice for people with multiple sclerosis. MS Australia works in advocacy and communications and collaborates with their stakeholders to benefit thousands of people affected by MS across the country. MS Research Australia and MS Australia are writing to support the inclusion of eculizumab on the Pharmaceutical Benefits Scheme (PBS) for people with NMOSD. The Centre for Community-Driven Research is keen to inform the PBAC about the experience of people with NMOSD and their expectations of new treatments. The NMOSD community in Australia is not represented by a national peak body and as NMOSD and MS have some similarities, we are proud to advocate on behalf of those living with NMOSD. One area we are all particularly passionate about is the provision of affordable and accessible treatments that can improve the lives of people with NMOSD. About NMOSD NMOSD is a recently defined inflammatory disorder of the central nervous system (CNS) that was previously either misdiagnosed as MS or identified as Devic’s disease.
    [Show full text]
  • Cimzia (Certolizumab Pegol) AHM
    Cimzia (Certolizumab Pegol) AHM Clinical Indications • Cimzia (Certolizumab Pegol) is considered medically necessary for adult members 18 years of age or older with moderately-to-severely active disease when ALL of the following conditions are met o Moderately-to-severely active Crohn's disease as manifested by 1 or more of the following . Diarrhea . Abdominal pain . Bleeding . Weight loss . Perianal disease . Internal fistulae . Intestinal obstruction . Megacolon . Extra-intestinal manifestations: arthritis or spondylitis o Crohn's disease has remained active despite treatment with 1 or more of the following . Corticosteroids . 6-mercaptopurine/azathioprine • Certollizumab pegol (see note) is considered medically necessary for persons with active psoriatic arthritis who meet criteria in Psoriasis and Psoriatic Arthritis: Biological Therapies. • Cimzia, (Certolizumab Pegol), alone or in combination with methotrexate (MTX), is considered medically necessary for the treatment of adult members 18 years of age or older with moderately-to-severely active rheumatoid arthritis (RA). • Cimzia (Certolizumab pegol is considered medically necessary for reducing signs and symptoms of members with active ankylosing spondylitis who have an inadequate response to 2 or more NSAIDs. • Cimzia (Certolizumab Pegol) is considered investigational for all other indications (e.g.,ocular inflammation/uveitis; not an all-inclusive list) because its effectiveness for indications other than the ones listed above has not been established. Notes • There are several brands of targeted immune modulators on the market. There is a lack of reliable evidence that any one brand of targeted immune modulator is superior to other brands for medically necessary indications. Enbrel (etanercept), Humira (adalimumab), Remicade (infliximab), Simponi (golimumab), Simponi Aria (golimumab intravneous), and Stelara (ustekinumab) brands of targeted immune modulators ("least cost brands of targeted immune modulators") are less costly to the plan.
    [Show full text]
  • Ocrelizumab And
    Ocrelizumab and PML As of May 2019, there have been 7 confirmed cases of carry-over PMLa in MS patients treated with Prescribing information* ocrelizumab, out of more than 100,000 patients treated globally (clinical trials and post-marketing experience); no unconfoundedb cases have been reported: Progressive Multifocal Leukoencephalopathy (PML) is an opportunistic viral infection of the brain caused by the Report Date Case Description John Cunningham (JC) virus that typically only occurs in Case was from a compassionate-use program in a JCV+ patient who switched to ocrelizumab after 36 infusions of natalizumab. patients who are immunocompromised, and that usually May 2017 Assessment of the case resulted in it being reported to regulators as related to natalizumab and not ocrelizumab.3 leads to death or severe disability. The patient had increasingly worsening neurological symptoms and MRI changes prior to discontinuing treatment with Although no cases of PML were identified in fingolimod in December 2017. The patient started treatment with ocrelizumab in March/April 2018. In April 2018, MRI changes, April 2018 ocrelizumab clinical trials, a risk of PML cannot be worsening clinical presentation and JCV DNA in the CSF confirmed the diagnosis of PML. The case was reported to regulators ruled out since JC virus infection resulting in PML as a carry-over PML from fingolimod as assessed by the physician.4 has been observed in patients treated with anti-CD20 A JCV+ patient was previously treated with natalizumab for 7 years. Due to MRI changes and worsening clinical symptoms, antibodies and other MS therapies and associated with April 2018 natalizumab was discontinued in February 2018.
    [Show full text]
  • Biosim™ Natalizumab (Tysabri®) (Human) ELISA
    FOR RESEARCH USE ONLY! ™ BioSim Natalizumab (Tysabri®) (Human) ELISA Kit 07/20 (Catalog # E4856-100, 96 assays, Store at 4°C) I. Introduction: Natalizumab is a humanized IgG4k monoclonal antibody produced in murine myeloma cells. Natalizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to a4-integrin. Natalizumab is used to treat multiple sclerosis-MS. It is thought to help by preventing patient’s immune system from attacking the nerves in the brain and spinal cord. Natalizumab is also used to treat a bowel condition called Crohn's disease (CD). BioSim™ Natalizumab ELISA kit has been developed for specific quantification of Natalizumab concentration in human serum or plasma with high sensitivity and reproducibility. Natalizumab ELISA kit is based on the sandwich ELISA principle. Standards and samples (serum or plasma) are added in the microtiter plate coated with the reactant for Natalizumab. After incubation, the wells are washed. The HRP conjugated probe is added and binds to Natalizumab captured by the reactant on the surface of the wells. Following incubation wells are washed and the bound enzymatic activity is detected by addition of TMB chromogen substrate. Finally, the reaction is terminated with an acidic stop solution. The color developed is proportional to the amount of Natalizumab in the sample or standard. Results of samples can be determined directly using the standard curve. II. Application: This ELISA kit is used for in vitro quantitative determination of Natalizumab Detection Range: 30 - 1000 ng/ml Sensitivity: 3 ng/ml Assay Precision: Intra-Assay: CV < 30%; Inter-Assay: CV < 30% (CV (%) = SD/mean X 100) Recovery rate: <100±30% with normal human serum samples with known concentrations Cross Reactivity: Except for Natalizumab, there is no cross reaction with other therapeutic antibodies and native serum immunoglobins.
    [Show full text]
  • WO 2016/176089 Al 3 November 2016 (03.11.2016) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2016/176089 Al 3 November 2016 (03.11.2016) P O P C T (51) International Patent Classification: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, A01N 43/00 (2006.01) A61K 31/33 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (21) International Application Number: KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, PCT/US2016/028383 MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (22) International Filing Date: PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, 20 April 2016 (20.04.2016) SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 62/154,426 29 April 2015 (29.04.2015) US TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (71) Applicant: KARDIATONOS, INC. [US/US]; 4909 DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, Lapeer Road, Metamora, Michigan 48455 (US).
    [Show full text]
  • Tysabri® (Natalizumab)
    UnitedHealthcare® Commercial Medical Benefit Drug Policy Tysabri® (Natalizumab) Policy Number: 2021D0026M Effective Date: May 1, 2021 Instructions for Use Table of Contents Page Community Plan Policy Coverage Rationale ....................................................................... 1 • Tysabri® (Natalizumab) Applicable Codes .......................................................................... 2 Background.................................................................................... 3 Benefit Considerations .................................................................. 3 Clinical Evidence ........................................................................... 4 U.S. Food and Drug Administration ............................................. 6 References ..................................................................................... 7 Policy History/Revision Information ............................................. 8 Instructions for Use ....................................................................... 8 Coverage Rationale See Benefit Considerations Tysabri (natalizumab) is proven for the treatment of: Relapsing Forms of Multiple Sclerosis Tysabri (natalizumab) is medically necessary for the treatment of relapsing forms of multiple sclerosis (MS) when all of the following are met:1 Initial Therapy o Diagnosis of relapsing forms of multiple sclerosis (MS) (e.g., clinically isolated syndrome, relapsing-remitting disease, active secondary-progressive disease); and o Patient is not receiving Tysabri
    [Show full text]
  • The Age-Related Efficacy of Dimethyl Fumarate and Natalizumab in the Real-World Management of Multiple Sclerosis
    pharmaceuticals Article The Age-Related Efficacy of Dimethyl Fumarate and Natalizumab in the Real-World Management of Multiple Sclerosis Roberto De Masi 1,2 , Stefania Orlando 1,* and Antonella De Donno 3 1 Laboratory of Neuroproteomics, Multiple Sclerosis Centre, “F. Ferrari” Hospital, 73042 Casarano, Lecce, Italy; [email protected] 2 Complex Operative Unit of Neurology, “F. Ferrari” Hospital, 73042 Casarano, Lecce, Italy 3 Laboratory of Hygiene, Department of Biological and Environmental Sciences and Technologies, University of the Salento, 73100 Lecce, Italy; [email protected] * Correspondence: [email protected]; Tel.: +39-0833-508-412 Abstract: We investigated the comparative age-related efficacy of dimethyl fumarate (DMF) and natalizumab (NTZ) in clinical practice on multiple sclerosis (MS). Research in this area is lacking in the previous literature. In a three-year retrospective and clinical–paraclinical study, we compared 173 DMF patients and 94 NTZ patients with a similar average age (40 years) and disease duration (DD) (10 years). Expanded Disability Status Scale (EDSS) scores were higher in the NTZ group than in the DMF group at 3.5 vs. 2.5, respectively (p = 0.001). However, in both groups, age values correlated with DD (r = 0.42; p < 0.001), EDSS (r = 0.52; p < 0.001) and age at onset (r = 0.18; p < 0.001). Furthermore, age-adjusted Kaplan–Meier curves showed that NTZ-treated subjects maintained a 1.0–3.0 EDSS status score (p = 0.003) more frequently and a 3.5–7.0 score (p = 0.022) significantly less frequently compared with DMF-treated subjects.
    [Show full text]
  • TYSABRI (Natalizumab) Injection, for Intravenous Use • Observe Patients During the Infusion and for One Hour After the Infusion Is Complete Initial U.S
    HIGHLIGHTS OF PRESCRIBING INFORMATION ---------------------------------DOSAGE AND ADMINISTRATION --------------------------------­ These highlights do not include all the information needed to use TYSABRI • 300 mg infused intravenously over one hour, every four weeks. Do not give as an safely and effectively. See full prescribing information for TYSABRI. intravenous push or bolus (2.1, 2.2) • TYSABRI solution must be administered within 8 hours of preparation (2.3) TYSABRI (natalizumab) injection, for intravenous use • Observe patients during the infusion and for one hour after the infusion is complete Initial U.S. Approval: 2004 (2.4) • In CD, discontinue in patients that have not experienced therapeutic benefit by 12 WARNING: PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY weeks of induction therapy, and in patients that cannot discontinue chronic See full prescribing information for complete boxed warning concomitant steroids within six months of starting therapy (2.2) • TYSABRI increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to ---------------------------------DOSAGE FORMS AND STRENGTH -------------------------------­ death or severe disability (5.1) Solution [300 mg per 15 mL vial] for dilution prior to infusion (3) • Risk factors for the development of PML include duration of therapy, prior use of immunosuppressants, and presence of anti-JCV antibodies. These -----------------------------------------CONTRAINDICATIONS --------------------------------------­
    [Show full text]
  • Aquaporin-4 Antibodies in Patients Treated with Natalizumab for Suspected MS
    Aquaporin-4 antibodies in patients treated with natalizumab for suspected MS Anna Gahlen, MD ABSTRACT Anne-Kathrin Trampe, Objective: To evaluate (1) the frequency of aquaporin-4 antibody (AQP4-ab)-seropositive cases PhD among patients treated with natalizumab (NAT) and previously diagnosed with MS (MSNAT)in Steffen Haupeltshofer, a nationwide cohort, (2) the clinical course of NAT-treated AQP4-ab–seropositive neuromyelitis MSc optica spectrum disorder (NMOSD) patients (NMONAT), (3) AQP4-ab titers in NMONAT and AQP4- Marius Ringelstein, MD ab–seropositive NMOSD treated with other immunotherapies (NMOIT), and (4) immune mecha- Orhan Aktas, MD nisms influencing disease activity in NMONAT. Achim Berthele, MD Methods: MSNAT serum samples were retrospectively screened with a cell-based assay for AQP4- Brigitte Wildemann, MD IgG and titers determined by ELISA. The annualized relapse rate (ARR) and disability progression Ralf Gold, MD were assessed. Serum levels of proinflammatory cytokines (interleukin [IL]-1b, IL-4, IL-6, IL-8, IL- Sven Jarius, MD 10, IL-17, IL-21, and interferon [IFN]-g) and the chemokine CXCL-10 of NMONAT patients Ingo Kleiter, MD identified in this (n 5 4) and a previous study (n 5 5) were measured by cytometric bead array and ELISA. Correspondence to Results: Of the 1,183 MSNAT patients (851 female, median 9 NAT infusions), only 4 (0.33%; 3 Prof. Kleiter: female, 1 male) had AQP4-IgG. Of these, 2 fulfilled the 2006 NMO criteria and all met the 2015 [email protected] NMOSD criteria. The ARR was higher in NMONAT vs MSNAT (p 5 0.0182). All 4 NMONAT patients had relapses and 2 had an increase of disability.
    [Show full text]